Research Paper Volume 13, Issue 14 pp 19048—19063

Combined treatment with C16 peptide and angiopoietin-1 confers neuroprotection and reduces inflammation in 3-nitropropionic acid-induced dystonia mice

C16 +Ang-l treatment can alleviate abnormal synchronous muscle contractions detected using electrophysiological methods. (A–F) Muscle contraction wave profiles showing the amplitude (uV) of the (A, B) control, (C, D) 3-NP, and (E, F) 3-NP+C16+Ang-1 groups. Synchronous contraction of agonist (quadriceps femoris) and antagonist (biceps femoris) muscles indicated dystonia in the 3-NP group. This phenomenon of synchronous muscle contraction was alleviated by C16+Ang-1 treatment. (G) Quantification of the amplitude observed for each group. aP bP

Figure 2. C16 +Ang-l treatment can alleviate abnormal synchronous muscle contractions detected using electrophysiological methods. (AF) Muscle contraction wave profiles showing the amplitude (uV) of the (A, B) control, (C, D) 3-NP, and (E, F) 3-NP+C16+Ang-1 groups. Synchronous contraction of agonist (quadriceps femoris) and antagonist (biceps femoris) muscles indicated dystonia in the 3-NP group. This phenomenon of synchronous muscle contraction was alleviated by C16+Ang-1 treatment. (G) Quantification of the amplitude observed for each group. aP < 0.05 versus control; bP < 0.05 versus 3-NP-treated mice.